StockData
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. (COYA) stock

COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.09+0.07 (+2.32%)

Close on Nov 18, 2026Market cap $72.48MP/E –Yield –

Coya Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Coya Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$31.67M. For fiscal 2025 it was -$22.56M. The highest annual figure on record is -$4.87M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.56M–
FY2024Dec 31, 2024-$17.25M–
FY2023Dec 31, 2023-$7.90M–
FY2022Dec 31, 2022-$9.81M–
FY2021Dec 31, 2021-$4.87M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$10.95M–
Q2 FY2026Jun 30, 2026-$7.05M–
Q1 FY2026Mar 31, 2026-$7.64M–
Q4 FY2025Dec 31, 2025-$6.03M–
Q3 FY2025Sep 30, 2025-$2.43M–
Q2 FY2025Jun 30, 2025-$6.41M–
Q1 FY2025Mar 31, 2025-$7.68M–
Q4 FY2024Dec 31, 2024-$4.08M-324.8%
Q3 FY2024Sep 30, 2024-$4.45M–
Q2 FY2024Jun 30, 2024-$3.24M–
Q1 FY2024Mar 31, 2024-$5.48M–
Q4 FY2023Dec 31, 2023$1.82M–
Q3 FY2023Sep 30, 2023-$3.56M–
Q2 FY2023Jun 30, 2023-$3.25M–
Q1 FY2023Mar 31, 2023-$2.90M–
Q4 FY2022Dec 31, 2022-$2.00M–
Q3 FY2022Sep 30, 2022-$2.66M–
Q2 FY2022Jun 30, 2022-$3.45M–
Q1 FY2022Mar 31, 2022-$1.70M–

More Coya Therapeutics figures

See a number that looks wrong?